Pine announces expansion completion, tripling facility size and doubling workforce

Sep 21, 2022 | Company news

After the announcement of our expansion in December 2021, Pine Pharmaceuticals is pleased to share the completion of our 50,000-square-foot state-of-the-art facility. Designed to comply with the US Food and Drug Administration’s Current Good Manufacturing Practice (cGMP), Pine is now triple the size, strengthening our ability to address drug shortages nationwide.

In addition, Pine exceeded initial employment projections, producing approximately 90 new full-time positions across several departments in less than two years. Given the noteworthy accomplishment, Alfonse Muto, Owner of Pine Pharmaceuticals, went on to share his sentiments on the achievement: 

“We are proud to be leading the charge right here in Western New York by creating dozens of new jobs and providing essential pharmaceuticals that will dramatically improve patient care across the country.” 

As one of the nation’s leading 503B outsourcing facilities, Pine Pharmaceuticals is continuously working to earn our reputation for uncompromising quality and responsive innovations. That is why we would like to sincerely thank our partners for their support during our expansion, as the promise of our mission would have been incomplete without you. 

You can read more about Pine Pharmaceuticals’ completed expansion here:


Pine Pharmaceuticals 503b facility expansion 2022

Pine Pharmaceuticals is an FDA-registered, cGMP-compliant 503B outsourcing facility. For more information, please visit or email to learn more about our products and services.